Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients.

Kuragano T, Matsumura O, Matsuda A, Hara T, Kiyomoto H, Murata T, Kitamura K, Fujimoto S, Hase H, Joki N, Fukatsu A, Inoue T, Itakura I, Nakanishi T.

Kidney Int. 2014 Oct;86(4):845-54. doi: 10.1038/ki.2014.114. Epub 2014 Apr 23.

PMID:
24759150
2.

ESA and iron therapy in chronic kidney disease: a balance between patient safety and hemoglobin target.

Hung SC, Tarng DC.

Kidney Int. 2014 Oct;86(4):676-8. doi: 10.1038/ki.2014.179.

PMID:
25265951
3.

Low levels of serum ferritin lead to adequate hemoglobin levels and good survival in hemodialysis patients.

Ogawa C, Tsuchiya K, Kanda F, Maeda T.

Am J Nephrol. 2014;40(6):561-70. doi: 10.1159/000370317. Epub 2015 Jan 10.

PMID:
25592750
4.

The impact of hyporesponsiveness to erythropoietin-stimulating agents on time-dependent mortality risk among CKD stage 5D patients: a single-center cohort study.

Ishigami J, Onishi T, Shikuma S, Akita W, Mori Y, Asai T, Kuwahara M, Sasaki S, Tsukamoto Y.

Clin Exp Nephrol. 2013 Feb;17(1):106-14. doi: 10.1007/s10157-012-0659-6. Epub 2012 Jul 3.

PMID:
22752396
5.

Understanding the Recent Increase in Ferritin Levels in United States Dialysis Patients: Potential Impact of Changes in Intravenous Iron and Erythropoiesis-Stimulating Agent Dosing.

Karaboyas A, Zee J, Morgenstern H, Nolen JG, Hakim R, Kalantar-Zadeh K, Zager P, Pisoni RL, Port FK, Robinson BM.

Clin J Am Soc Nephrol. 2015 Oct 7;10(10):1814-21. doi: 10.2215/CJN.02600315. Epub 2015 Aug 18.

6.

Coefficient of variation among ferritin measurement methods in hemodialysis and standard serum ferritin level.

Kamei D, Akiba T.

Kidney Int. 2015 Jul;88(1):197. doi: 10.1038/ki.2015.126. No abstract available.

PMID:
26126098
7.

Association of a change in erythropoiesis-stimulating agent dose during hospitalization and subsequent hemoglobin levels and transfusions in hemodialysis patients.

Wong BC, Ravani P, Manns BJ, Lewin A, Zhang X, Chin R, Hemmelgarn BR, Tonelli M, Oliver MJ, Quinn RR.

Am J Kidney Dis. 2013 Nov;62(5):947-52. doi: 10.1053/j.ajkd.2013.05.017. Epub 2013 Jul 12.

PMID:
23856380
8.

2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.

Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T.

Ther Apher Dial. 2010 Jun;14(3):240-75. doi: 10.1111/j.1744-9987.2010.00836.x.

PMID:
20609178
9.

ESA Hyporesponsiveness Is Associated with Adverse Events in Maintenance Hemodialysis (MHD) Patients, But Not with Iron Storage.

Kuragano T, Kitamura K, Matsumura O, Matsuda A, Hara T, Kiyomoto H, Murata T, Fujimoto S, Hase H, Joki N, Fukatsu A, Inoue T, Itakura Y, Nakanishi T.

PLoS One. 2016 Mar 2;11(3):e0147328. doi: 10.1371/journal.pone.0147328. eCollection 2016.

10.

Effect of protoconized therapy for renal anemia on adverse events of patients with maintenance hemodialysis.

Kuragano T, Yahiro M, Kida A, Furuta M, Nagasawa Y, Hasuike Y, Nanami M, Nakanishi T.

Int J Artif Organs. 2014 Dec;37(12):865-74. doi: 10.5301/ijao.5000370. Epub 2014 Nov 29.

PMID:
25450320
11.

Renal anaemia treatment in haemodialysis patients in the Central and Eastern European countries in everyday clinical practice follow-up.

Malyszko J, Drozdz M, Zolkiewicz A, Rutkowski B.

Int Urol Nephrol. 2014 Jan;46(1):71-82. doi: 10.1007/s11255-012-0303-0. Epub 2012 Nov 8.

12.

The impact of ferritin fluctuations on stable hemoglobin levels in hemodialysis patients.

Yahiro M, Kuragano T, Kida A, Kitamura R, Furuta M, Hasuike Y, Otaki Y, Nonoguchi H, Nakanishi T.

Clin Exp Nephrol. 2012 Jun;16(3):448-55. doi: 10.1007/s10157-011-0584-0. Epub 2012 Jan 24.

PMID:
22270185
13.

Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients.

Sibbel SP, Koro CE, Brunelli SM, Cobitz AR.

BMC Nephrol. 2015 Aug 18;16:144. doi: 10.1186/s12882-015-0138-x.

14.

Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia.

Majoni SW, Ellis JA, Hall H, Abeyaratne A, Lawton PD.

Hemodial Int. 2014 Oct;18(4):740-50. doi: 10.1111/hdi.12173. Epub 2014 Apr 27.

PMID:
24766376
15.

Treatment with high dose of erythropoiesis-stimulating agents and mortality: analysis with a sequential Cox approach and a marginal structural model.

Suttorp MM, Hoekstra T, Mittelman M, Ott I, Krediet RT, Dekker FW, Putter H.

Pharmacoepidemiol Drug Saf. 2015 Oct;24(10):1068-75. doi: 10.1002/pds.3855. Epub 2015 Aug 12.

PMID:
26265483
16.
17.

[Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B-4 chronic kidney disease: A new direction of cardionephroprotection].

Milovanov YS, Mukhin NA, Kozlovskaya LV, Milovanova SY, Markina MM.

Ter Arkh. 2016;88(6):21-25. doi: 10.17116/terarkh201688621-25. Russian.

PMID:
27296257
18.

Higher doses of erythropoietin-stimulating agents and hyporesponsiveness to their effects are associated with increased mortality among prevalent hemodialysis patients.

Nishio A, Chhatkuli BP, Ma JZ, Kalantari K.

Blood Purif. 2013;36(1):29-36. doi: 10.1159/000350583. Epub 2013 May 25.

PMID:
23735569
19.

Low versus high dose erythropoiesis-stimulating agents in hemodialysis patients with anemia: A randomized clinical trial.

Saglimbene V, Palmer SC, Craig JC, Ruospo M, Nicolucci A, Tonelli M, Johnson D, Lucisano G, Williams G, Valentini M, D'Alonzo D, Pellegrini F, Strippoli P, Salomone M, Santoro A, Maffei S, Hegbrant J, Tognoni G, Strippoli GF; CE-DOSE Study Investigators.

PLoS One. 2017 Mar 1;12(3):e0172735. doi: 10.1371/journal.pone.0172735. eCollection 2017.

20.

Current management of anemia in adult hemodialysis patients with end-stage renal disease.

Frankenfield DL, Johnson CA.

Am J Health Syst Pharm. 2002 Mar 1;59(5):429-35.

PMID:
11887409

Supplemental Content

Support Center